Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $25.00 Price Target at Bank of America

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target lowered by Bank of America from $28.00 to $25.00 in a research report report published on Tuesday,Benzinga reports. Bank of America currently has a buy rating on the stock.

Several other research analysts have also recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $35.86.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $12.20 on Tuesday. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -11.84 and a beta of -1.46. The stock’s fifty day moving average price is $13.49 and its two-hundred day moving average price is $13.97. Day One Biopharmaceuticals has a one year low of $11.94 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the company posted ($0.54) earnings per share. On average, equities analysts anticipate that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $16.10, for a total value of $161,000.00. Following the transaction, the insider now owns 1,057,535 shares in the company, valued at $17,026,313.50. The trade was a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 51,745 shares of company stock worth $748,567 over the last three months. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in Day One Biopharmaceuticals by 178.5% during the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock worth $103,254,000 after purchasing an additional 4,750,936 shares in the last quarter. Braidwell LP grew its stake in shares of Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock worth $67,893,000 after buying an additional 1,837,949 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Day One Biopharmaceuticals by 2.3% during the third quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock worth $55,336,000 after buying an additional 87,262 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of Day One Biopharmaceuticals by 65.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after acquiring an additional 1,157,825 shares during the last quarter. Finally, Vestal Point Capital LP boosted its holdings in shares of Day One Biopharmaceuticals by 100.0% during the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,250,000 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.